Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Related Clinical Trial
Clinical Trial to Evaluate Safety and Efficacy of Cell Therapy in Patients With Cicatricial Conjuntivitis. Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren’s Syndrome, and Graft Vs Host Disease LYell SYndrome MEsenchymal Stromal Cells Treatment Severe Bullous Drug Eruption and Filgrastim Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Severe Cutaneous Adverse Reactions in Thailand Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Stevens-Johnson Syndrome Antimicrobial Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye G-CSF in the Treatment of Toxic Epidermal Necrolysis Corneal Epitheliotropic Factors in Autologous Serum Eye Drops in Nonautoimmune and Stevens-Johnson Syndrome With Dry Eye Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Topical Infliximab in Autoimmune Eyes With Keratoprosthesis HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction Drug Reactions Sampling (COLLECTIONTOXIDERMIES) Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN) Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis NATIENS: Optimal Management and Mechanisms of SJS/TEN

Brief Title

Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Official Title

A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis

Brief Summary

      This is a prospective, multicenter cohort observational; study to compare treatment outcomes
      in patients admitted to the hospital with Stevens-Johnsons Syndrome/Toxic Epidermolysis,
      aiming to assess the utility of medical management. The hypothesis of this study is that one
      or more treatment options will demonstrate improved patient outcomes. The primary objectives
      are cessation of progression of disease, time to complete re-epithelialization, length of
      stay, and mortality rate in the treatment groups as compared to those receiving supportive
      care alone. Exploratory analyses will assess the cause, risk factors, and severity prediction
      factors associated with the disease.

Study Type


Primary Outcome



Stevens-Johnson Syndrome


Site specific standard of care comparison

Study Arms / Comparison Groups



* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 1, 2021

Completion Date

December 31, 2021

Primary Completion Date

December 31, 2021

Eligibility Criteria

        Inclusion Criteria:

          -  a diagnosis of Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis confirmed by
             examination of a dermatologist and/or skin biopsy plus described appropriate clinical
             findings (epidermal necrosis plus two involved mucosal surfaces) presenting within one
             week of disease onset

        Exclusion Criteria:

          -  Pregnancy

          -  Age <18y

          -  Decisional impairment

          -  Incarceration

          -  Onset of skin separation >7d




18 Years - N/A

Accepts Healthy Volunteers

Accepts Healthy Volunteers


, , 

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Massachusetts General Hospital

Study Sponsor

, , 

Verification Date

December 2020